Last updated: September 8, 2026
Fiasp is Novo Nordisk’s faster-acting insulin aspart product, approved in the United States in 2017 for mealtime treatment of diabetes. Its commercial position depends on premium pricing for faster absorption, insulin-pump compatibility, delivery-device access, and Novo Nordisk’s broader insulin franchise. Novo Nordisk does not disclose standalone Fiasp revenue, so its financial trajectory must be inferred from insulin aspart sales, the company’s diabetes-care results, pricing trends, and competitive activity.
Fiasp faces increasing market pressure from Lilly’s Lyumjev, conventional insulin aspart products, biosimilar and follow-on insulin pathways, payer formularies, and the shift in Novo Nordisk’s growth profile toward GLP-1 and obesity medicines.
What is Fiasp and how does it differ from NovoLog?
Fiasp contains insulin aspart, the same active insulin analog used in NovoLog and NovoRapid. Its formulation includes excipients intended to accelerate early insulin absorption after injection. Novo Nordisk markets Fiasp in vial, FlexTouch prefilled pen, and pump-compatible presentations in relevant markets.
| Attribute |
Fiasp |
NovoLog/NovoRapid |
| Active ingredient |
Insulin aspart |
Insulin aspart |
| Manufacturer |
Novo Nordisk |
Novo Nordisk |
| FDA approval |
2017 |
2000 |
| Primary use |
Mealtime insulin |
Mealtime insulin |
| Differentiation |
Faster early absorption |
Conventional rapid-acting profile |
| Delivery |
Vial, pen, pump-compatible forms |
Vial, pen, pump-compatible forms |
| Main US competitor |
Lyumjev |
Humalog, Lyumjev, generic insulin aspart |
| Regulatory category |
Biologic |
Biologic after insulin transition |
FDA approved Fiasp under NDA 208751. The label identifies the product as insulin aspart with niacinamide and other formulation components that support faster initial exposure after dosing.[1]
Fiasp is not a new insulin molecule. Its commercial value comes from formulation, pharmacokinetic timing, delivery-device integration, and physician and patient adoption.
What is the FDA regulatory and exclusivity status of Fiasp?
Fiasp received FDA approval on September 29, 2017. FDA approval did not create the same type of long-duration market exclusivity associated with a new chemical entity because insulin aspart had already been approved and the product represented a new formulation and delivery profile.
The key regulatory milestones are:
| Date |
Event |
| 2000 |
NovoLog, insulin aspart, approved in the US |
| 2017 |
Fiasp approved by FDA |
| 2017-2018 |
Fiasp launched in the US and other major markets |
| 2020 |
Insulin products transitioned from the drug pathway to the biologics framework |
| 2020 onward |
Biosimilar and interchangeable-insulin pathways became relevant to insulin competition |
| 2022 |
FDA expanded Fiasp labeling for pediatric patients aged 1 year and older |
| 2024 |
Fiasp remained an active Novo Nordisk mealtime-insulin product in the US market |
The 2020 regulatory transition moved insulin products from the Federal Food, Drug, and Cosmetic Act framework into the Public Health Service Act framework. FDA stated that approved insulin products would be treated as biologics, creating a formal pathway for biosimilar and interchangeable insulin competition.[2]
Fiasp therefore does not rely primarily on FDA exclusivity. Its protection depends on patents, formulation differentiation, manufacturing know-how, device integration, clinical familiarity, and payer positioning.
What patents protect Fiasp?
Fiasp protection is expected to center on formulation and use rather than the insulin aspart molecule itself. Insulin aspart is an established active ingredient with earlier composition-of-matter protection no longer controlling market access.
The relevant protection categories include:
- Formulations containing insulin aspart and absorption-modifying excipients.
- Use of faster-acting insulin aspart in mealtime treatment.
- Stable liquid formulations suitable for injection.
- Cartridge, pen, and pump presentations.
- Manufacturing, storage, and stability processes.
- Combination use with continuous glucose-monitoring and insulin-delivery systems.
The central commercial issue is whether a competing insulin-aspart product can enter with a materially different formulation and avoid valid claims covering Fiasp’s excipient combination or delivery profile. A conventional insulin aspart biosimilar may not reproduce Fiasp’s formulation and still compete for a large portion of the same rapid-acting insulin market.
Fiasp’s patent estate should be assessed by jurisdiction and claim scope rather than by counting patent families. The most valuable claims are likely those that cover the formulation and its faster absorption characteristics. Device patents generally provide narrower protection because a competitor may use a different pen, cartridge, or pump presentation.
A definitive expiration date for the entire Fiasp patent estate cannot be assigned from the product label or FDA approval date. Patent terms vary by filing date, patent-term adjustment, terminal disclaimers, patent-term extension, and jurisdiction. Fiasp’s regulatory approval date is not its patent expiration date.
Is Fiasp listed in the Orange Book?
Fiasp should not be analyzed as a conventional Orange Book small-molecule product. After the 2020 insulin transition, insulin products are regulated as biologics. The relevant reference-product and biosimilar framework is the Purple Book and FDA biologics records, not ordinary Orange Book listing practice.[2,3]
This distinction affects generic litigation strategy:
- A conventional ANDA Paragraph IV challenge is not the primary pathway for insulin products regulated as biologics.
- A biosimilar applicant may use the 351(k) pathway.
- An interchangeable designation may provide additional substitution potential.
- Patent disputes may arise through the Biologics Price Competition and Innovation Act patent-exchange process and subsequent federal litigation.
- Product-specific formulation patents can remain commercially important even when the active insulin molecule is old.
When does Fiasp lose exclusivity?
Fiasp does not have a single, publicly disclosed loss-of-exclusivity date comparable to a small-molecule product with one Orange Book composition patent.
Its effective exclusivity period is determined by four factors:
| Factor |
Effect on Fiasp |
| Regulatory exclusivity |
Limited relative to a new active ingredient |
| Formulation patents |
Can delay closely matched faster-acting products |
| Biologic competition |
Permits biosimilar and interchangeable-insulin entry |
| Payer contracts |
Can reduce commercial protection before patent expiry |
Fiasp’s market protection can erode before all formulation patents expire. Payers can prefer lower-cost insulin aspart, Humalog, Lyumjev, or authorized generic alternatives while Fiasp remains patent-protected. Conversely, clinical differentiation may preserve a premium segment where patients value earlier post-meal action or pump performance.
What is Fiasp’s financial trajectory?
Novo Nordisk does not report Fiasp revenue as a separate line item. The company reports broader product and therapeutic-area categories, which prevents a precise Fiasp revenue estimate from public annual reports.
Novo Nordisk’s financial trajectory has two opposing effects on Fiasp:
- The company’s overall sales and cash generation have expanded rapidly because of Ozempic, Wegovy, and related GLP-1 products.
- Traditional insulin growth has been weaker because of pricing pressure, payer controls, biosimilar competition, and portfolio migration toward newer diabetes therapies.
Fiasp’s revenue likely has a mature-product profile rather than a high-growth launch profile. Initial uptake benefited from its differentiated pharmacokinetics and Novo Nordisk’s established insulin distribution. Later growth has been constrained by:
- Insulin price compression in the United States.
- Greater use of preferred formulary products.
- Competition from Lyumjev.
- Continued use of lower-cost NovoLog and insulin aspart alternatives.
- Patient switching driven by deductibles and copayment exposure.
- Greater therapeutic emphasis on GLP-1 medicines for type 2 diabetes.
- Flat or slower growth in intensive insulin therapy compared with obesity medicine.
| Financial driver |
Likely impact on Fiasp |
| Premium formulation |
Supports higher net price than standard insulin aspart in selected channels |
| US rebates |
Reduces realized revenue |
| Novo Nordisk scale |
Supports distribution and contracting |
| Lyumjev competition |
Limits share expansion |
| Biosimilar insulin |
Increases long-term price pressure |
| Pump use |
Supports retention in intensive-therapy patients |
| GLP-1 substitution in type 2 diabetes |
Reduces addressable insulin growth |
| Insulin affordability policy |
Creates downside risk to gross-to-net revenue |
Fiasp’s financial contribution is strategically relevant but unlikely to be material relative to Novo Nordisk’s semaglutide franchise. The product is more important as part of Novo Nordisk’s complete insulin portfolio and customer-retention strategy than as a standalone growth engine.
How does Fiasp compare with Lyumjev and standard insulin aspart?
The principal branded comparison is Lilly’s Lyumjev, which contains insulin lispro and uses formulation technology intended to accelerate absorption.
| Product |
Company |
Active insulin |
Commercial positioning |
| Fiasp |
Novo Nordisk |
Insulin aspart |
Faster-acting mealtime insulin |
| Lyumjev |
Eli Lilly |
Insulin lispro |
Ultra-rapid mealtime insulin |
| NovoLog/NovoRapid |
Novo Nordisk |
Insulin aspart |
Established rapid-acting insulin |
| Humalog |
Eli Lilly |
Insulin lispro |
Established rapid-acting insulin |
| Admelog |
Sanofi |
Insulin lispro |
Lower-cost lispro alternative |
| Generic insulin aspart products |
Multiple manufacturers |
Insulin aspart |
Lower-cost competition where available |
Clinical differentiation between Fiasp and Lyumjev is narrower than the difference between either product and regular human insulin. Physicians typically evaluate post-meal glucose control, hypoglycemia, pump performance, injection timing, formulary status, and patient preference.
The competitive battleground is therefore commercial as much as clinical. A product with modest pharmacokinetic advantages can lose share if it carries a substantially higher patient cost.
What generic and biosimilar entry risks exist for Fiasp?
Fiasp faces three levels of competitive risk.
Conventional insulin-aspart competition
Products using insulin aspart without Fiasp’s exact formulation can compete on price. These products may be most disruptive in formularies that prioritize molecule-level substitution rather than faster absorption.
Biosimilar or interchangeable insulin competition
Because insulin is now regulated as a biologic, a competitor can pursue a 351(k) application. An interchangeable designation could increase pharmacy-level substitution, although state substitution laws, payer contracts, device differences, and prescriber preference remain important.
Formulation-matched competition
The highest-risk entrant would reproduce Fiasp’s faster-acting formulation and secure comparable injection and pump presentations. This path would face the greatest formulation, patent, analytical, clinical, manufacturing, and regulatory hurdles.
The commercial threat is likely to develop gradually. Insulin markets are heavily contracted, device-dependent, and sensitive to supply reliability. A lower-priced product does not automatically capture share unless it obtains formulary access and supports the delivery systems used by patients.
What patent litigation and Paragraph IV risks affect Fiasp?
No major, widely reported Fiasp-specific Paragraph IV litigation should be assumed from the product’s biologic status. Paragraph IV litigation is associated with ANDA filings and does not map cleanly onto the post-2020 biologic treatment of insulin.
Future disputes may instead involve:
- Patent challenges to Fiasp formulation claims.
- BPCIA patent-exchange activity.
- Declaratory-judgment actions over noninfringement or invalidity.
- Disputes involving pen, cartridge, pump, or manufacturing patents.
- Contract litigation over formulary and supply arrangements.
Novo Nordisk’s most meaningful legal exposure is likely to be portfolio-wide rather than limited to Fiasp. A biosimilar entrant may challenge several insulin products at once, while Fiasp-specific claims could remain relevant only to a faster-acting formulation.
What licensing deals affect Fiasp?
Fiasp is an internally developed Novo Nordisk product. There is no widely disclosed licensing transaction that defines its market access or revenue model. Novo Nordisk controls the core commercial franchise, manufacturing network, regulatory filings, and branded distribution.
External relationships can still affect Fiasp indirectly through:
- Insulin-pump manufacturers.
- Diabetes-device companies.
- Pharmacy benefit managers.
- Wholesalers and specialty distributors.
- Government purchasing programs.
- Contract manufacturing and fill-finish suppliers.
The absence of a major product-level license means Fiasp economics are primarily determined by Novo Nordisk’s own manufacturing costs, rebates, distribution terms, and channel mix.
What is the investment and commercial outlook for Fiasp?
Fiasp is a defensible but mature insulin product. Its strongest commercial attributes are Novo Nordisk’s brand, physician familiarity, supply infrastructure, and faster-acting formulation. Its principal weaknesses are limited molecule-level novelty, price-sensitive insulin markets, competing ultra-rapid insulin products, and the availability of lower-cost alternatives.
The base-case outlook is stable-to-declining revenue contribution over the medium term, with continued use in patients who value faster mealtime action or have established pump routines. Growth would require increased pump adoption, favorable formulary placement, broader use in type 1 diabetes, or stronger evidence that its timing profile produces clinically meaningful benefits for targeted patients.
Key Takeaways
- Fiasp is insulin aspart with a faster-acting formulation, not a new insulin molecule.
- FDA approved Fiasp in 2017 under NDA 208751.
- Novo Nordisk does not disclose standalone Fiasp revenue.
- Fiasp’s financial contribution is likely mature and smaller than Novo Nordisk’s GLP-1 franchise.
- Formulation, delivery, manufacturing, and method-of-use patents matter more than composition-of-matter protection.
- The 2020 insulin transition makes the Purple Book and BPCIA framework more relevant than ordinary Orange Book analysis.
- Lyumjev is Fiasp’s principal branded ultra-rapid competitor.
- Biosimilar and interchangeable-insulin competition create long-term pricing risk.
- No single public loss-of-exclusivity date captures the entire Fiasp patent estate.
- Formulary access and net pricing are likely to determine revenue before complete patent exhaustion.
FAQs
Is Fiasp more expensive than NovoLog?
Fiasp often carries a higher list price or net price than lower-cost insulin aspart alternatives, but actual patient and payer costs depend on rebates, insurance design, manufacturer programs, and formulary placement.
Can a biosimilar replace Fiasp automatically at the pharmacy?
Automatic substitution depends on FDA interchangeability status, state law, payer policy, product presentation, and pharmacy practice. A biosimilar to insulin aspart is not necessarily interchangeable with the specific Fiasp formulation.
Does Fiasp have a new chemical entity exclusivity period?
No. Fiasp uses the established insulin aspart molecule. Its market protection depends primarily on formulation, device, manufacturing, regulatory, and commercial barriers.
Is Fiasp approved for insulin pumps?
Fiasp is approved for subcutaneous use and pump administration under specified labeling conditions. Pump compatibility must be evaluated against the current FDA label and the specific pump system.
Will GLP-1 drugs eliminate the market for Fiasp?
No. GLP-1 drugs can reduce insulin use in some patients with type 2 diabetes, but intensive insulin therapy remains essential for many patients with type 1 diabetes and continues to serve patients requiring prandial insulin.
References
-
U.S. Food and Drug Administration. (2024). Fiasp insulin aspart prescribing information. FDA.
-
U.S. Food and Drug Administration. (2020). Insulin products regulated under the Public Health Service Act. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
Novo Nordisk A/S. (2024). Annual report 2023. Novo Nordisk.
-
U.S. Food and Drug Administration. (2000). NovoLog insulin aspart prescribing information. FDA.
